Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions
- PMID: 9165689
- PMCID: PMC2589004
Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions
Abstract
Omeprazole, lansoprazole and pantoprazole are metabolized by several human cytochromes P450, most prominently by CYP2C19 and CYP3A4. Only pantoprazole is also metabolized by a sulfotransferase. Differences in the quantitative contribution of these enzymes and in the relative affinities of the substrates explain some of the observed interactions with carbamazepin, diazepam, phenytoin and theophylline and of the impact of the CYP2C19 (mephenytoin) genetic polymorphism. Of these drugs, pantoprazole has the lowest potential for interactions, both in vitro and in human volunteer studies.
Similar articles
-
Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.Eur J Gastroenterol Hepatol. 1996 Oct;8 Suppl 1:S21-5. doi: 10.1097/00042737-199610001-00005. Eur J Gastroenterol Hepatol. 1996. PMID: 8930576
-
Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies.Clin Ther. 1999 Oct;21(10):1812-9. doi: 10.1016/S0149-2918(99)80059-9. Clin Ther. 1999. PMID: 10566575
-
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.Drug Metab Dispos. 1997 Jul;25(7):853-62. Drug Metab Dispos. 1997. PMID: 9224780
-
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.Am Fam Physician. 2007 Aug 1;76(3):391-6. Am Fam Physician. 2007. PMID: 17708140 Review.
-
Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole.Dig Dis Sci. 1991 Dec;36(12):1665-9. doi: 10.1007/BF01296606. Dig Dis Sci. 1991. PMID: 1748033 Review.
Cited by
-
CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication.Eur J Clin Pharmacol. 2011 Mar;67(3):261-6. doi: 10.1007/s00228-010-0928-9. Epub 2010 Nov 16. Eur J Clin Pharmacol. 2011. PMID: 21079935
-
Pharmacokinetic drug-drug interaction and their implication in clinical management.J Res Med Sci. 2013 Jul;18(7):601-10. J Res Med Sci. 2013. PMID: 24516494 Free PMC article. Review.
-
What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?Pharmaceutics. 2021 Feb 25;13(3):301. doi: 10.3390/pharmaceutics13030301. Pharmaceutics. 2021. PMID: 33668911 Free PMC article. Review.
-
Pharmacokinetics of proton pump inhibitors in children.Clin Pharmacokinet. 2005;44(5):441-66. doi: 10.2165/00003088-200544050-00001. Clin Pharmacokinet. 2005. PMID: 15871633 Review.
-
Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN).Support Care Cancer. 2025 May 20;33(6):484. doi: 10.1007/s00520-025-09528-0. Support Care Cancer. 2025. PMID: 40394328 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources